Biomarker Insights (Jan 2019)

The Fraction Exhaled Nitric Oxide as a Biomarker of Asthma Control

  • Fernanda Cruvinel de Abreu,
  • Jose Laerte Rodrigues da Silva Júnior,
  • Marcelo Fouad Rabahi

DOI
https://doi.org/10.1177/1177271919826550
Journal volume & issue
Vol. 14

Abstract

Read online

Introduction and Objective: The main goal of asthma treatment is to achieve and maintain clinical control of the disease. The exhaled fraction nitric oxide (FeNO) level is a biomarker of T-helper cell type 2 (Th2) inflammation of the airways. Our objective was to determine whether the FeNO level can be used to discriminate between patients with controlled, partially controlled, and uncontrolled asthma. Materials and Methods: The FeNO level and asthma control were evaluated in a retrospective and analytic cross-sectional study through data collected from asthmatic patients who were assessed by clinical history, asthma control, physical examination, spirometry, and FeNO level. Asthma control was determined by the criteria of the Global Initiative for Asthma and classified as controlled asthma, partially controlled asthma, and uncontrolled asthma. The FeNO values were classified as low (30 ppb was associated with uncontrolled asthma ( P = .0001) with an area under the receiver operating characteristic curve of 0.78 (95% confidence interval = 0.65-0.89). Conclusions: FeNO level could be helpful in determining asthma control as >30 ppb was associated with uncontrolled asthma.